Acadian Asset Management
PVLA

Acadian Asset Management’s Palvella Therapeutics PVLA Stock Holding History

Acadian Asset Management’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1
Closed – – 2047
2025
Q2 		$0 Buy
+1
New +$23 ﹤0.01% 1874
2025
Q1 		– Sell
-1,549
Closed -$18K – 1844
2024
Q4 		$18K Sell
1,549
-1,464
-49% -$23K ﹤0.01% 1549
2024
Q3 		$49K Sell
3,013
-7,814
-72% -$114K ﹤0.01% 1798
2024
Q2 		$106K Sell
10,827
-1,202
-10% -$13.6K ﹤0.01% 1530
2024
Q1 		$175K Hold
12,029
– – ﹤0.01% 1203
2023
Q4 		$174K Hold
12,029
– – ﹤0.01% 1258
2023
Q3 		$286K Buy
12,029
+4,729
+65% +$102K ﹤0.01% 1128
2023
Q2 		$96K Sell
7,300
-584
-7% -$35.4K ﹤0.01% 1411
2023
Q1 		$615K Sell
7,884
-3,139
-28% -$364K ﹤0.01% 1006
2022
Q4 		$916K Buy
11,023
+1,507
+16% +$121K ﹤0.01% 868
2022
Q3 		$874K Sell
9,516
-453
-5% -$58.4K ﹤0.01% 841
2022
Q2 		$1.49M Buy
9,969
+5,584
+127% +$1.02M 0.01% 711
2022
Q1 		$1.06M Buy
4,385
+44
+1% +$11.6K ﹤0.01% 815
2021
Q4 		$1.31M Buy
4,341
+3,437
+380% +$1.1M ﹤0.01% 762
2021
Q3 		$373K Sell
904
-1,076
-54% -$375K ﹤0.01% 1131
2021
Q2 		$607K Sell
1,980
-8,040
-80% -$1.76M ﹤0.01% 1080
2021
Q1 		$2.06M Sell
10,020
-947
-9% -$207K 0.01% 724
2020
Q4 		$2.19M Sell
10,967
-812
-7% -$169K 0.01% 729
2020
Q3 		$1.95M Buy
11,779
+2,027
+21% +$462K 0.01% 673
2020
Q2 		$2.42M Buy
9,752
+1,566
+19% +$366K 0.01% 685
2020
Q1 		$1.49M Buy
8,186
+630
+8% +$159K 0.01% 679
2019
Q4 		$2.19M Sell
7,556
-16,037
-68% -$4.45M 0.01% 656
2019
Q3 		$6.43M Sell
23,593
-4,382
-16% -$1.7M 0.03% 415
2019
Q2 		$10.5M Hold
27,975
– – 0.05% 278
2019
Q1 		$7.5M Hold
27,975
– – 0.03% 363
2018
Q4 		$5.96M Buy
27,975
+885
+3% +$275K 0.03% 348
2018
Q3 		$12.1M Buy
27,090
+529
+2% +$230K 0.05% 261
2018
Q2 		$10.8M Buy
26,561
+8,300
+45% +$3.95M 0.05% 289
2018
Q1 		$9.96M Buy
18,261
+16,809
+1,158% +$10.4M 0.04% 305
2017
Q4 		$877K Buy
1,452
+178
+14% +$82.8K ﹤0.01% 713
2017
Q3 		$587K Buy
1,274
+873
+218% +$373K ﹤0.01% 766
2017
Q2 		$162K Buy
+401
New +$117K ﹤0.01% 972

Other funds holding PVLA

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Acadian Asset Management's PVLA Position: Q3 2025 in Review

Acadian Asset Management sold out of Palvella Therapeutics (PVLA) in Q3 2025, closing a stake of 1 share.

Acadian Asset Management first reported a position in PVLA in Q2 2017 and held it in 32 quarters. The position peaked at $12.1M in Q3 2018. 100 funds tracked by Wall St. Rank hold PVLA as of Q3 2025.

  • Acadian Asset Management reported no remaining Palvella Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Acadian Asset Management sold 1 Palvella Therapeutics share in Q3 2025.
  • Acadian Asset Management first reported a position in Palvella Therapeutics in Q2 2017 and held it in 32 quarters.
  • Acadian Asset Management's Palvella Therapeutics position peaked at $12.1M in Q3 2018.
  • 100 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q3 2025.

Based on Acadian Asset Management's 13F filing for Q3 2025, filed 13 Nov 2025.